Table I.
Number and distribution of individuals analyzed for overall and post-diagnostic hazard of glioblastoma death and post-diagnostic hazard of glioblastoma recurrence and level of the cohort factors considered.
| Post-diagnostic survival (overall survival)a | Post-diagnostic recurrence (progression-free survival) | ||||
|---|---|---|---|---|---|
| Number | Percentage | Number | Percentage | ||
| Total | 253 | 192 | |||
|
| |||||
| N Censored | 26 | 10% | 17 | 9% | |
| Race | Caucasian | 211 | 83% | 161 | 84% |
| Other | 42 | 17% | 31 | 16% | |
| Gender | Females | 91 | 36% | 68 | 35% |
| Males | 162 | 64% | 124 | 65% | |
| Therapy | RX | 38 | 15% | 32 | 17% |
| CRN | 133 | 53% | 113 | 59% | |
| CRT | 31 | 12% | 28 | 15% | |
| OTHER | 51 | 20% | 19 | 10% | |
| Recurrence | Yes | 192 | 76% | 192 | 100% |
| No | 61 | 24% | 0 | 0% | |
a
The number of patients analyzed for post-diagnostic survival and life expectancy is the same.
N, Number of patients; RX, radiation therapy alone; CRN, chemotherapy plus radiation and no targeted therapy; CRT, chemotherapy plus radiation and targeted therapy; OTHER, all other therapies including no therapy.